Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design
Abstract
Trifluridine/tipiracil (FTD/TPI) is an orally active formulation of trifluridine, a thymidine-based nucleoside analog, and tipiracil hydrochloride, a thymidine phosphorylase inhibitor that increases the bioavailability of trifluridine. Preliminary studies of FTD/TPI plus bevacizumab have produced encouraging results in the treatment of refractory metastatic colorectal cancer. Here, we describe the design of the multinational Phase III SUNLIGHT, an open-label study of FTD/TPI plus bevacizumab as third-line treatment for patients with unresectable metastatic colorectal cancer. A total of 490 patients will be randomized 1:1 to receive either FTD/TPI plus bevacizumab, or FTD/TPI monotherapy. The primary objective is to significantly improve overall survival with FTD/TPI plus bevacizumab compared with FTD/TPI monotherapy. The first patient was enrolled in November 2020.
Keywords
Bevacizumab; Metastatic colorectal cancer; Trifluridine/tipiracil
Bibliographic citation
Tabernero J, Taieb J, Prager GW, Ciardiello F, Fakih M, Leger C, et al. Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. Futur Oncol. 2021 Jun;17(16):1977–1985.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/6146This item appears in following collections
- HVH - Articles científics [2972]
- VHIO - Articles científics [865]
The following license files are associated with this item: